Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Feb 19;16(14):1163-1169.
doi: 10.4244/EIJ-D-20-00268.

Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial

Michalis Hamilos  1 , John Kanakakis, Ioannis Anastasiou, Charalambos Karvounis, Vasilios Vasilikos, John Goudevenos, Lampros Michalis, Michalis Koutouzis, Ioannis Tsiafoutis, Konstantinos Raisakis, Dimitrios Stakos, George Hahalis, Panos Vardas; Collaborators
Collaborators, Affiliations
Randomized Controlled Trial

Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial

Michalis Hamilos et al. EuroIntervention. .

Abstract

Aims: We aimed to demonstrate whether coronary microvascular function is improved after ticagrelor administration compared to clopidogrel administration in STEMI subjects undergoing thrombolysis.

Methods and results: MIRTOS is a multicentre study of ticagrelor versus clopidogrel in STEMI subjects treated with fibrinolysis. We enrolled 335 patients <75 years old with STEMI eligible for thrombolysis, of whom 167 were randomised to receive clopidogrel and 168 to receive ticagrelor together with thrombolysis. Primary outcome was the difference in post-PCI corrected TIMI frame count (CTFC). All clinical events were recorded in a three-month follow-up period. From the 335 patients who were randomised, 259 underwent PCI (129 clopidogrel and 130 ticagrelor) and 154 angiographies were analysable for the study primary endpoint. No significant difference was found between the clopidogrel (n=85) and ticagrelor (n=69) groups for CTFC (24.33±17.35 vs 28.33±17.59, p=0.10). No significant differences were observed in MACE and major bleeding events between randomisation groups (OR 2.0, 95% CI: 0.18-22.2, p=0.99).

Conclusions: Thrombolysis with ticagrelor in patients <75 years old was not able to demonstrate superiority compared to clopidogrel in terms of microvascular injury, while there was no difference between the two groups in MACE and major bleeding events.

Trial registration: ClinicalTrials.gov Identifier: NCT02429271. EudraCT Number 2014-004082-25.

PubMed Disclaimer

Conflict of interest statement

M. Hamilos reports grants and personal fees from HCRS, and personal fees from AstraZeneca and Sanofi. J. Kanakakis reports grants from HCRS, and personal fees from AstraZeneca and Sanofi. I. Anastasiou reports non-financial support from HCRS. C. Karvounis reports non-financial support from HCRS, and personal fees from AstraZeneca. J. Goudevenos reports non-financial support from HCRS. L. Michalis reports personal fees from Sanofi, AstraZeneca, Elpen and Bayer Hellas. M. Koutouzis reports grants from HCRS. I. Tsiafoutis reports grants from HCRS and AstraZeneca. K. Raisakis reports grants from HCRS. D. Stakos reports grants from HCRS. P. Vardas reports personal fees from Menarini International, Dean Medicus, Servier, the European Society of Cardiology and Hygeia Hospitals Group. I. Mantas reports non-financial support from HCRS. E. Foukarakis reports grants from HCRS. G. Papaioannou reports non-financial support from HCRS. G. Ikonomou reports non-financial support from HCRS. A. Damelou reports grants from HCRS. I. Samiotis reports non-financial support from HCRS. N. Kampouridis reports non-financial support from HCRS. I. Tsounos reports non-financial support from HCRS. G. Chlouverakis reports grants from HCRS. G. Kochiadakis reports non-financial support from HCRS, personal fees from AstraZeneca and Sanofi, and grants from Innovis, Servier and Abbott. S. Petousis reports grants from HCRS. E. Skalidis reports grants from HCRS, and personal fees from AstraZeneca, Medtronic, Boehringer-Ingelheim and Pfizer. E. Zacharis reports non-financial support from HCRS, and personal fees from Sanofi and Amgen. F. Parthenakis reports grants from HCRS. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Study flow diagram.
Figure 2
Figure 2
Mean corrected Thrombolysis In Myocardial Infarction (TIMI) frame count values (cTFC) in each randomisation group.
See this image and copyright information in PMC

References

    1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57. - PubMed
    1. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;12:1188–99. doi: 10.1161/CIRCULATIONAHA.109.919456. - DOI - PubMed
    1. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919–33. - PubMed
    1. Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19:209–19. doi: 10.1177/1074248413511693. - DOI - PubMed
    1. Ohman J, Kudira R, Albinsson S, Olde B, Erlinge D. Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun. 2012;418:754–8. doi: 10.1016/j.bbrc.2012.01.093. - DOI - PubMed

Publication types

Associated data